likely to show a relative excess of rare variants. Indeed, we believe that PrediXcan offers intriguing opportunities to combine results of rare and common variant association tests within whole genome sequencing studies, and more generally, to combine results of rare variant gene-based tests from sequencing studies with results of PrediXcan gene-based tests from the large body of existing GWAS for the same phenotypes. Thus, PrediXcan is a method developed to integrate –omics data that can facilitate integration of results from common and rare variant studies.
